Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Terns Announces Positive Data from Phase I Trial of NASH Candidate

publication date: Feb 19, 2020

Terns Pharma, a Shanghai-San Francisco biopharma, reported TERN-101, a potential treatment for NASH, was well tolerated and seemed to engage its FXR target in a US Phase I trial. The trial was a randomized, double-blind, placebo-controlled study designed to evaluate safety, pharmacokinetics, pharmacodynamics and plasma biomarkers of FXR pathway activation. It enrolled 36 healthy participants who received placebo or TERN-101 at various dose levels for seven days. Terns said biomarker studies showed reductions in levels that imply efficacy in treating liver fibrosis. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China